Requirement for V(α)14 NKT cells in IL-12-mediated rejection of tumors

Science

Volumn 278, Issue 5343, 1997, Pages 1623-1626

  Cui, Junqing ^a   Shin, Tahiro ^a   Kawano, Tetsu ^a   Sato, Hiroshi ^a   Kondo, Eisuke ^a   Toura, Isao ^a   Kaneko, Yoshikatsu ^a   Koseki, Haruhiko ^a   Kanno, Masamoto ^a   Taniguchi, Masaru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; ANTIINFECTIVE AGENT; CONCANAMYCIN A; GAMMA INTERFERON; LYMPHOCYTE ANTIGEN RECEPTOR; MACROLIDE; POLYINOSINIC POLYCYTIDYLIC ACID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ARTICLE; GENE DELETION; GENE TARGETING; KILLER CELL; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; RECEPTOR GENE; TARGET CELL; TUMOR REJECTION; ANIMAL; C57BL MOUSE; CYTOTOXICITY; DRUG ANTAGONISM; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; GENE; GENETICS; IMMUNOLOGY; MOUSE; NATURAL KILLER CELL; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOTOXICITY, IMMUNOLOGIC; GENE DELETION; GENE TARGETING; GENES, RAG-1; GENES, T-CELL RECEPTOR ALPHA; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; MACROLIDES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; POLY I-C; PROTON-TRANSLOCATING ATPASES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS;

EID: 0030613856     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.278.5343.1623     Document Type: Article

References (52)

1. B. J. Fowlkes et al., Nature 329, 251 (1987); R. C. Budd et al., J. Exp. Med. 166, 577 (1987).
2. B. J. Fowlkes et al., Nature 329, 251 (1987); R. C. Budd et al., J. Exp. Med. 166, 577 (1987).
3. Y. Makino et al., J. Exp. Med. 177, 1399 (1993); Y. Makino, R. Kanno, H. Koseki, M. Taniguchi, Proc. Natl. Acad. Sci. U.S.A. 93, 6516 (1996).
4. Y. Makino et al., J. Exp. Med. 177, 1399 (1993); Y. Makino, R. Kanno, H. Koseki, M. Taniguchi, Proc. Natl. Acad. Sci. U.S.A. 93, 6516 (1996).
5. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
6. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
7. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
8. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
9. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
10. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
11. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
12. Z. K. Ballas and W. Rasmussen, J. Immunol. 145, 1039 (1990); M. Sykes, ibid., p. 3209; H. I. Levitsky, P. T. Golumbek, D. M. Pardoll, ibid. 146, 1113 (1991); Y. Takahama, A. Kosugi, A. Singer, ibid., p. 1134; S. Koyasu et al., J. Exp. Med. 175, 203 (1992); M. Six, M. Coles, D. Raulet, ibid. 178, 901 (1993); A. Bendelac, N. Killeen, D. R. Littman, R. H. Schwartz, Science 263, 1774 (1994); T. Ohteki and H. R. MacDonald, J. Exp. Med. 180, 699 (1994).
13. Y. Makino, R. Kanno, T. Ito, K. Higashino, M. Taniguchi, Int. Immunol. 7, 1157 (1995).
14. K. Masuda et al., J. Immunol. 158, 2076 (1997).
15. K. Imai et al., Proc. Natl. Acad. Sci. U.S.A. 83, 8708 (1986).
16. O. Lantz and A. Bendelac, J. Exp. Med. 180, 1097 (1994).
17. M. Taniguchi et al., Proc. Natl. Acad. Sci. U.S.A. 93, 11025 (1996).
18. M. Kobayashi et al., J. Exp. Med. 170, 827 (1989); A. S. Stern et al., Proc. Natl. Acad. Sci. U.S.A. 87, 6808 (1990); S. F. Wolf et al., J. Immunol. 146, 3074 (1991); M. K. Gately et al., ibid. 147, 874 (1991); D. S. Schoenhaut et al., ibid. 148, 3433 (1992).
19. M. Kobayashi et al., J. Exp. Med. 170, 827 (1989); A. S. Stern et al., Proc. Natl. Acad. Sci. U.S.A. 87, 6808 (1990); S. F. Wolf et al., J. Immunol. 146, 3074 (1991); M. K. Gately et al., ibid. 147, 874 (1991); D. S. Schoenhaut et al., ibid. 148, 3433 (1992).
20. M. Kobayashi et al., J. Exp. Med. 170, 827 (1989); A. S. Stern et al., Proc. Natl. Acad. Sci. U.S.A. 87, 6808 (1990); S. F. Wolf et al., J. Immunol. 146, 3074 (1991); M. K. Gately et al., ibid. 147, 874 (1991); D. S. Schoenhaut et al., ibid. 148, 3433 (1992).
21. M. Kobayashi et al., J. Exp. Med. 170, 827 (1989); A. S. Stern et al., Proc. Natl. Acad. Sci. U.S.A. 87, 6808 (1990); S. F. Wolf et al., J. Immunol. 146, 3074 (1991); M. K. Gately et al., ibid. 147, 874 (1991); D. S. Schoenhaut et al., ibid. 148, 3433 (1992).
22. M. Kobayashi et al., J. Exp. Med. 170, 827 (1989); A. S. Stern et al., Proc. Natl. Acad. Sci. U.S.A. 87, 6808 (1990); S. F. Wolf et al., J. Immunol. 146, 3074 (1991); M. K. Gately et al., ibid. 147, 874 (1991); D. S. Schoenhaut et al., ibid. 148, 3433 (1992).
23. W. Hashimoto et al., J. Immunol. 154, 4333 (1995); M. Takahashi et al., ibid. 156, 2436 (1996).
24. W. Hashimoto et al., J. Immunol. 154, 4333 (1995); M. Takahashi et al., ibid. 156, 2436 (1996).
25. A. Nagy, J. Rossant, R. Nagy, W. Abramow-Newerly, J. C. Roder, Proc. Natl. Acad. Sci. U.S.A. 90, 8424 (1993); T. Akasaka et al., Development 122, 1513 (1996).
26. A. Nagy, J. Rossant, R. Nagy, W. Abramow-Newerly, J. C. Roder, Proc. Natl. Acad. Sci. U.S.A. 90, 8424 (1993); T. Akasaka et al., Development 122, 1513 (1996).
27. H. Koseki et al., Proc. Natl. Acad. Sci. U.S.A. 87, 5248 (1990).
28. L. Kopper, T. Van Hanh, K. Lapis, J. Cancer Res. Clin. Oncol. 103, 31 (1982); E. Barbera-Guillem, A. Alosno-Varona, F. Vidal-Vanadocha, Cancer Res. 49, 4003 (1989); M. Tardif, J. Coulombe, D. Soulieres, A. P. Rousseau, G. Pelletier, Int. J. Cancer 68, 97 (1996).
29. L. Kopper, T. Van Hanh, K. Lapis, J. Cancer Res. Clin. Oncol. 103, 31 (1982); E. Barbera-Guillem, A. Alosno-Varona, F. Vidal-Vanadocha, Cancer Res. 49, 4003 (1989); M. Tardif, J. Coulombe, D. Soulieres, A. P. Rousseau, G. Pelletier, Int. J. Cancer 68, 97 (1996).
30. L. Kopper, T. Van Hanh, K. Lapis, J. Cancer Res. Clin. Oncol. 103, 31 (1982); E. Barbera-Guillem, A. Alosno-Varona, F. Vidal-Vanadocha, Cancer Res. 49, 4003 (1989); M. Tardif, J. Coulombe, D. Soulieres, A. P. Rousseau, G. Pelletier, Int. J. Cancer 68, 97 (1996).
31. T. Kawano et al., Science 278, 1626 (1997).
32. B. A. Teicher, G. Ara, K. Menon, R. G. Schaub, Int. J. Cancer 65, 80 (1996).
33. C. L. Nastala et al., J. Immunol. 153, 1697 (1994); J.-P. Zou et al., Int. Immunol. 7, 1135 (1995).
34. C. L. Nastala et al., J. Immunol. 153, 1697 (1994); J.-P. Zou et al., Int. Immunol. 7, 1135 (1995).
35. M. J. Brunda et al., J. Exp. Med. 178, 1223 (1993).
36. J. Cui and T. Shin, data not shown.
37. T. Kataoka et al., J. Immunol. 156, 3678 (1996); K. Ando et al., ibid. 158, 5283 (1997).
38. T. Kataoka et al., J. Immunol. 156, 3678 (1996); K. Ando et al., ibid. 158, 5283 (1997).
39. L. K. Chen et al., Eur. J. Immunol. 16, 767 (1986); E. Maraskovsky, W.-F. Chen, K. Shortman, J. Immunol. 143, 1210 (1989); M. J. Brunda, D. Rosenbaum, L. Stern, Int. J. Cancer 34, 421 (1984); D. A. Weigent, G. J. Stanton, H. M. Johnson, Biochem. Biophys. Res. Commun. 111, 525 (1983).
40. L. K. Chen et al., Eur. J. Immunol. 16, 767 (1986); E. Maraskovsky, W.-F. Chen, K. Shortman, J. Immunol. 143, 1210 (1989); M. J. Brunda, D. Rosenbaum, L. Stern, Int. J. Cancer 34, 421 (1984); D. A. Weigent, G. J. Stanton, H. M. Johnson, Biochem. Biophys. Res. Commun. 111, 525 (1983).
41. L. K. Chen et al., Eur. J. Immunol. 16, 767 (1986); E. Maraskovsky, W.-F. Chen, K. Shortman, J. Immunol. 143, 1210 (1989); M. J. Brunda, D. Rosenbaum, L. Stern, Int. J. Cancer 34, 421 (1984); D. A. Weigent, G. J. Stanton, H. M. Johnson, Biochem. Biophys. Res. Commun. 111, 525 (1983).
42. L. K. Chen et al., Eur. J. Immunol. 16, 767 (1986); E. Maraskovsky, W.-F. Chen, K. Shortman, J. Immunol. 143, 1210 (1989); M. J. Brunda, D. Rosenbaum, L. Stern, Int. J. Cancer 34, 421 (1984); D. A. Weigent, G. J. Stanton, H. M. Johnson, Biochem. Biophys. Res. Commun. 111, 525 (1983).
43. T. Shin and J. Cui, data not shown.
44. 125l-labeled M2590 mAb to melanoma as described [S. Wakabayashi, S. Okamoto, M. Taniguchi, Jpn. J. Cancer Res. 75, 427 (1984); Y. Gunji and M. Taniguchi, ibid. 77, 595 (1986); G. A. Nores, T. Dohi, M. Taniguchi, S. Hakomori, J. Immunol. 139, 3171 (1987)].
45. 125l-labeled M2590 mAb to melanoma as described [S. Wakabayashi, S. Okamoto, M. Taniguchi, Jpn. J. Cancer Res. 75, 427 (1984); Y. Gunji and M. Taniguchi, ibid. 77, 595 (1986); G. A. Nores, T. Dohi, M. Taniguchi, S. Hakomori, J. Immunol. 139, 3171 (1987)].
46. 125l-labeled M2590 mAb to melanoma as described [S. Wakabayashi, S. Okamoto, M. Taniguchi, Jpn. J. Cancer Res. 75, 427 (1984); Y. Gunji and M. Taniguchi, ibid. 77, 595 (1986); G. A. Nores, T. Dohi, M. Taniguchi, S. Hakomori, J. Immunol. 139, 3171 (1987)].
47. 5 cells were analyzed by EPICS-ELITE (Coulter Electronics, Hialeah, FL) with a logarithmic amplifier as described (5).
48. 6 B16 cells for subcutaneous tumor growth on day O. Recombinant murine IL-12 (2400 U/mouse) or phosphate-buffered saline (PBS) was injected on days 3, 5, 7, and 9. On day 14, the mice were killed and either metastatic nodules counted or GM3 melanoma antigens measured by radioimmunoassay in the liver or lung as described (22). For subcutaneous tumor growth, injection of IL-12 or PBS was initiated on day 5, and the mice were treated five times per week. The diameters of tumors were measured every day with calipers. The sizes of tumors were expressed as the products of the longest diameter times the shortest diameter (in square millimeters).
49. 51Cr-release was calculated by the following formula: percent of specific lysis = (sample cpm -spontaneous cpm) × 100/(maximum cpm - spontaneous cpm). Spontaneous cpm was calculated from the supernatant of the target cells alone, and the maximum release was obtained by adding 1N HCl to target cells.
50. β8 (MR5-2), NK1.1 (PK136), Ly49C (5E6), IFN-γ (R4-6A2), Fas (Jo2), and Fas ligand (K10) (Pharmingen) were used for blocking experiments.
51. S. Wakabayashi, M. Taniguchi, T. Tokuhisa, H. Tomioka, S. Okamoto, Nature 294, 748 (1981).
52. We thank M. Kobayashi and S. F. Wolf, Genetic Institute Incorporated, for recombinant murine IL-12 and H. Tanabe for secretarial assistance. Supported in part by the Grant-in-Aid for Scientific Research on Priority Areas (08282103) from the Ministry of Education, Culture, and Science, Japan and the Taisho Pharmaceutical Company.